Intra-pancreatic tissue-derived mesenchymal stromal cells: a promising therapeutic potential with anti-inflammatory and pro-angiogenic profiles
- PMID: 31730488
- PMCID: PMC6858763
- DOI: 10.1186/s13287-019-1435-2
Intra-pancreatic tissue-derived mesenchymal stromal cells: a promising therapeutic potential with anti-inflammatory and pro-angiogenic profiles
Abstract
Background: Human pancreata contain many types of cells, such as endocrine islets, acinar, ductal, fat, and mesenchymal stromal cells (MSCs). MSCs are important and shown to have a promising therapeutic potential to treat various disease conditions.
Methods: We investigated intra-pancreatic tissue-derived (IPTD) MSCs isolated from tissue fractions that are routinely discarded during pancreatic islet isolation of human cadaveric donors. Furthermore, whether pro-angiogenic and anti-inflammatory properties of these cells could be enhanced was investigated.
Results: IPTD-MSCs were expanded in GMP-compatible CMRL-1066 medium supplemented with 5% human platelet lysate (hPL). IPTD-MSCs were found to be highly pure, with > 95% positive for CD90, CD105, and CD73, and negative for CD45, CD34, CD14, and HLA-DR. Immunofluorescence staining of pancreas tissue demonstrated the presence of CD105+ cells in the vicinity of islets. IPTD-MSCs were capable of differentiation into adipocytes, chondrocytes, and osteoblasts in vitro, underscoring their multipotent features. When these cells were cultured in the presence of a low dose of TNF-α, gene expression of tumor necrosis factor alpha-stimulated gene-6 (TSG-6) was significantly increased, compared to control. In contrast, treating cells with dimethyloxallyl glycine (DMOG) (a prolyl 4-hydroxylase inhibitor) enhanced mRNA levels of nuclear factor erythroid 2-related factor 2 (NRF2) and vascular endothelial growth factor (VEGF). Interestingly, a combination of TNF-α and DMOG stimulated the optimal expression of all three genes in IPTD-MSCs. Conditioned medium of IPTD-MSCs treated with a combination of DMOG and TNF-α contained higher levels of pro-angiogenic (VEGF, IL-6, and IL-8) compared to controls, promoting angiogenesis of human endothelial cells in vitro. In contrast, levels of MCP-1, a pro-inflammatory cytokine, were reduced in the conditioned medium of IPTD-MSCs treated with a combination of DMOG and TNF-α.
Conclusions: The results demonstrate that IPTD-MSCs reside within the pancreas and can be separated as part of a standard islet-isolation protocol. These IPTD-MSCs can be expanded and potentiated ex vivo to enhance their anti-inflammatory and pro-angiogenic profiles. The fact that IPTD-MSCs are generated in a GMP-compatible procedure implicates a direct clinical application.
Keywords: Angiogenesis; Anti-inflammatory; Mesenchymal stromal cells; NRF2; TSG-6; Type 1 diabetes; VEGF.
Conflict of interest statement
BK, MQ, HTK, and IHA have patents pending related to this study. The other authors declare that they have no competing interests.
Figures









Similar articles
-
Regulatory-compliant conditions during cell product manufacturing enhance in vitro immunomodulatory properties of infrapatellar fat pad-derived mesenchymal stem/stromal cells.Cytotherapy. 2020 Nov;22(11):677-689. doi: 10.1016/j.jcyt.2020.06.007. Epub 2020 Jul 26. Cytotherapy. 2020. PMID: 32723596
-
Pancreas-derived mesenchymal stromal cells share immune response-modulating and angiogenic potential with bone marrow mesenchymal stromal cells and can be grown to therapeutic scale under Good Manufacturing Practice conditions.Cytotherapy. 2020 Dec;22(12):762-771. doi: 10.1016/j.jcyt.2020.07.010. Epub 2020 Aug 20. Cytotherapy. 2020. PMID: 32828673
-
Enhanced angiogenic activity of dimethyloxalylglycine-treated canine adipose tissue-derived mesenchymal stem cells.J Vet Med Sci. 2019 Dec 5;81(11):1663-1670. doi: 10.1292/jvms.19-0337. Epub 2019 Oct 2. J Vet Med Sci. 2019. PMID: 31582601 Free PMC article.
-
Mesenchymal stromal/stem cells from perinatal sources: biological facts, molecular biomarkers, and therapeutic promises.Stem Cell Res Ther. 2025 Mar 7;16(1):127. doi: 10.1186/s13287-025-04254-0. Stem Cell Res Ther. 2025. PMID: 40055783 Free PMC article. Review.
-
Mesenchymal stem cells and neovascularization: role of platelet-derived growth factor receptors.J Cell Mol Med. 2007 Sep-Oct;11(5):1012-30. doi: 10.1111/j.1582-4934.2007.00120.x. J Cell Mol Med. 2007. PMID: 17979880 Free PMC article. Review.
Cited by
-
The Feasibility and Applicability of Stem Cell Therapy for the Cure of Type 1 Diabetes.Cells. 2021 Jun 24;10(7):1589. doi: 10.3390/cells10071589. Cells. 2021. PMID: 34202521 Free PMC article. Review.
-
Human pancreatic islet-derived stromal cells reveal combined features of mesenchymal stromal cells and pancreatic stellate cells.Stem Cell Res Ther. 2024 Oct 8;15(1):351. doi: 10.1186/s13287-024-03963-2. Stem Cell Res Ther. 2024. PMID: 39380125 Free PMC article.
-
ABCB5+ Limbal Epithelial Stem Cells Inhibit Developmental but Promote Inflammatory (Lymph) Angiogenesis While Preventing Corneal Inflammation.Cells. 2023 Jun 27;12(13):1731. doi: 10.3390/cells12131731. Cells. 2023. PMID: 37443766 Free PMC article.
-
Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature.Cancer Cell Int. 2021 Mar 8;21(1):158. doi: 10.1186/s12935-021-01836-9. Cancer Cell Int. 2021. PMID: 33685452 Free PMC article. Review.
-
A molecular systems architecture of the mesenchymal stromal cell microenvironment.Stem Cells. 2025 Aug 22;43(9):sxaf042. doi: 10.1093/stmcls/sxaf042. Stem Cells. 2025. PMID: 40843515 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous